Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1985 Sep;54(3):298–304. doi: 10.1136/hrt.54.3.298

Usefulness of plasma renin activity in predicting haemodynamic and clinical responses and survival during long term converting enzyme inhibition in severe chronic heart failure. Experience in 100 consecutive patients.

M Packer, N Medina, M Yushak, W H Lee
PMCID: PMC481899  PMID: 2994697

Abstract

The relation between plasma renin activity before treatment and the haemodynamic and clinical responses to converting enzyme inhibition was determined in 100 consecutive patients with severe chronic heart failure who were treated with captopril or enalapril. Initial doses of captopril produced significant increases in cardiac index and decreases in left ventricular filling pressure, mean arterial pressure, mean right atrial pressure, heart rate, and systemic vascular resistance that varied linearly with the pretreatment value for plasma renin activity. In contrast, there was no relation between the pretreatment activity and the magnitude of haemodynamic improvement after 1-3 months of treatment with the converting enzyme inhibitors, and, consequently, a similar proportion of patients with a high (greater than 6 ng/ml/h; greater than 4.62 mmol/l/h), intermediate (2-6 ng/ml/h; 1.54-4.62 mmol/l/h), and low (less than 2 ng/ml/h; less than 1.54 mmol/l/h) pretreatment value improved clinically during long term treatment (64%, 60%, and 64% respectively). Long term survival after one, two, and three years was similar in the three groups. Estimating the degree of activation of the renin-angiotensin system by measuring pretreatment plasma renin activity fails to predict the long term haemodynamic or clinical responses to converting enzyme inhibitors in patients with severe chronic heart failure, and thus appears to be of limited value in selecting those patients likely to benefit from treatment with these drugs.

Full text

PDF
298

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ader R., Chatterjee K., Ports T., Brundage B., Hiramatsu B., Parmley W. Immediate and sustained hemodynamic and clinical improvement in chronic heart failure by an oral angiotensin-converting enzyme inhibitor. Circulation. 1980 May;61(5):931–937. doi: 10.1161/01.cir.61.5.931. [DOI] [PubMed] [Google Scholar]
  2. Arroyo V., Bosch J., Gaya-Beltrán J., Kravetz D., Estrada L., Rivera F., Rodés J. Plasma renin activity and urinary sodium excretion as prognostic indicators in nonazotemic cirrhosis with ascites. Ann Intern Med. 1981 Feb;94(2):198–201. doi: 10.7326/0003-4819-94-2-198. [DOI] [PubMed] [Google Scholar]
  3. Awan N. A., Evenson M. K., Needham K. E., Win A., Mason D. T. Efficacy of oral angiotensin-converting enzyme inhibition with captopril therapy in severe chronic normotensive congestive heart failure. Am Heart J. 1981 Jan;101(1):22–31. doi: 10.1016/0002-8703(81)90379-3. [DOI] [PubMed] [Google Scholar]
  4. Brunner H. R., Laragh J. H., Baer L., Newton M. A., Goodwin F. T., Krakoff L. R., Bard R. H., Bühler F. R. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med. 1972 Mar 2;286(9):441–449. doi: 10.1056/NEJM197203022860901. [DOI] [PubMed] [Google Scholar]
  5. Cody R. J., Franklin K. W., Kluger J., Laragh J. H. Sympathetic responsiveness and plasma norepinephrine during therapy of chronic congestive heart failure with captopril. Am J Med. 1982 May;72(5):791–797. doi: 10.1016/0002-9343(82)90547-2. [DOI] [PubMed] [Google Scholar]
  6. Cody R. J., Laragh J. H. Use of captopril to estimate renin-angiotensin-aldosterone activity in the pathophysiology of chronic heart failure. Am Heart J. 1982 Nov;104(5 Pt 2):1184–1189. doi: 10.1016/0002-8703(82)90049-7. [DOI] [PubMed] [Google Scholar]
  7. Cohn J. N., Levine T. B., Olivari M. T., Garberg V., Lura D., Francis G. S., Simon A. B., Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984 Sep 27;311(13):819–823. doi: 10.1056/NEJM198409273111303. [DOI] [PubMed] [Google Scholar]
  8. DICKINSON C. J., LAWRENCE J. R. A slowly developing pressor response to small concentrations of angiotensin. Its bearing on the pathogenesis of chronic renal hypertension. Lancet. 1963 Jun 22;1(7295):1354–1356. doi: 10.1016/s0140-6736(63)91929-9. [DOI] [PubMed] [Google Scholar]
  9. Davis R., Ribner H. S., Keung E., Sonnenblick E. H., LeJemtel T. H. Treatment of chronic congestive heart failure with captopril, an oral inhibitor of angiotensin-converting enzyme. N Engl J Med. 1979 Jul 19;301(3):117–121. doi: 10.1056/NEJM197907193010301. [DOI] [PubMed] [Google Scholar]
  10. Dzau V. J., Colucci W. S., Hollenberg N. K., Williams G. H. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation. 1981 Mar;63(3):645–651. doi: 10.1161/01.cir.63.3.645. [DOI] [PubMed] [Google Scholar]
  11. Faxon D. P., Halperin J. L., Creager M. A., Gavras H., Schick E. C., Ryan T. J. Angiotensin inhibition in severe heart failure: acute central and limb hemodynamic effects of captopril with observations on sustained oral therapy. Am Heart J. 1981 May;101(5):548–556. doi: 10.1016/0002-8703(81)90220-9. [DOI] [PubMed] [Google Scholar]
  12. Franciosa J. A., Dunkman W. B., Leddy C. L. Hemodynamic effects of vasodilators and long-term response in heart failure. J Am Coll Cardiol. 1984 Jun;3(6):1521–1530. doi: 10.1016/s0735-1097(84)80292-2. [DOI] [PubMed] [Google Scholar]
  13. Kluger J., Cody R. J., Laragh J. H. The contributions of sympathetic tone and the renin-angiotensin system to severe chronic congestive heart failure: response to specific inhibitors (prazosin and captopril). Am J Cardiol. 1982 May;49(7):1667–1674. doi: 10.1016/0002-9149(82)90244-2. [DOI] [PubMed] [Google Scholar]
  14. Kramer B. L., Massie B. M., Topic N. Controlled trial of captopril in chronic heart failure: a rest and exercise hemodynamic study. Circulation. 1983 Apr;67(4):807–816. doi: 10.1161/01.cir.67.4.807. [DOI] [PubMed] [Google Scholar]
  15. Levine T. B., Franciosa J. A., Cohn J. N. Acute and long-term response to an oral converting-enzyme inhibitor, captopril, in congestive heart failure. Circulation. 1980 Jul;62(1):35–41. doi: 10.1161/01.cir.62.1.35. [DOI] [PubMed] [Google Scholar]
  16. Maslowski A. H., Ikram H., Nicholls M. G., Espiner E. A. Haemodynamic, hormonal, and electrolyte responses to captopril in resistant heart failure. Lancet. 1981 Jan 10;1(8211):71–74. doi: 10.1016/s0140-6736(81)90004-0. [DOI] [PubMed] [Google Scholar]
  17. Massie B. M., Kramer B. L., Topic N. Lack of relationship between the short-term hemodynamic effects of captopril and subsequent clinical responses. Circulation. 1984 Jun;69(6):1135–1141. doi: 10.1161/01.cir.69.6.1135. [DOI] [PubMed] [Google Scholar]
  18. Massie B., Ports T., Chatterjee K., Parmley W., Ostland J., O'Young J., Haughom F. Long-term vasodilator therapy for heart failure: clinical response and its relationship to hemodynamic measurements. Circulation. 1981 Feb;63(2):269–278. doi: 10.1161/01.cir.63.2.269. [DOI] [PubMed] [Google Scholar]
  19. Packer M., Medina N., Yushak M., Meller J. Hemodynamic patterns of response during long-term captopril therapy for severe chronic heart failure. Circulation. 1983 Oct;68(4):803–812. doi: 10.1161/01.cir.68.4.803. [DOI] [PubMed] [Google Scholar]
  20. Packer M. Vasodilator and inotropic therapy for severe chronic heart failure: passion and skepticism. J Am Coll Cardiol. 1983 Nov;2(5):841–852. doi: 10.1016/s0735-1097(83)80230-7. [DOI] [PubMed] [Google Scholar]
  21. Riegger A. J., Lever A. F., Millar J. A., Morton J. J., Slack B. Correction of renal hypertension in the rat by prolonged infusion of angiotensin inhibitors. Lancet. 1977 Dec 24;2(8052-8053):1317–1319. doi: 10.1016/s0140-6736(77)90366-x. [DOI] [PubMed] [Google Scholar]
  22. Sharpe D. N., Murphy J., Coxon R., Hannan S. F. Enalapril in patients with chronic heart failure: a placebo-controlled, randomized, double-blind study. Circulation. 1984 Aug;70(2):271–278. doi: 10.1161/01.cir.70.2.271. [DOI] [PubMed] [Google Scholar]
  23. Swales J. D. Arterial wall or plasma renin in hypertension? Clin Sci (Lond) 1979 Apr;56(4):293–298. doi: 10.1042/cs0560293. [DOI] [PubMed] [Google Scholar]
  24. Thibonnier M., Soto M. E., Menard J., Aldiger J. C., Corvol P., Milliez P. Reduction of plasma and urinary vasopressin during treatment of severe hypertension by captopril. Eur J Clin Invest. 1981 Dec;11(6):449–453. doi: 10.1111/j.1365-2362.1981.tb02012.x. [DOI] [PubMed] [Google Scholar]
  25. Wenting G. J., de Bruyn J. H., Man in't Veld A. J., Woittiez A. J., Derkx F. H., Schalekamp M. A. Hemodynamic effects of captopril in essential hypertension, renovascular hypertension and cardiac failure: correlations with short- and long-term effects on plasma renin. Am J Cardiol. 1982 Apr 21;49(6):1453–1459. doi: 10.1016/0002-9149(82)90360-5. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES